KRATON RECEIVES ISCC PLUS CERTIFICATION FOR ITS NIORT MANUFACTURING FACILITY
THE WOODLANDS, Texas, March 27, 2025 /PRNewswire/ -- Kraton Corporation, a leading global producer of specialty polymers and high-value biobased products derived from by-products of pine wood pulping, is pleased to announce its manufacturing facility in Niort, France, has received an International Sustainability and Carbon Certification (ISCC) PLUS certification. The certification enables Kraton to offer 100% ISCC PLUS certified AMS and AMS Phenolics resins through a mass balance attribution method.
"Our SYLVARES™ and SYLVATRAXX™ brands feature a range of high-performance AMS and AMS Phenolics resins used in specialty adhesives and tire applications", said Lana Culbert, Kraton Pine Chemicals VP of Marketing. "Our ISCC PLUS journey began in 2021 with the certification of our Sandarne, Sweden facility. Earning this certification for our Niort plant marks a significant milestone, further expanding our portfolio of sustainable solutions."
The certification of the Niort facility reinforces Kraton's commitment to advancing the biobased and circular economy. By enabling customers to integrate more sustainable materials into their supply chains, Kraton remains at the forefront of sustainable innovations, dedicated to reducing carbon emissions and driving the transition toward a more sustainable future.
The International Sustainability and Carbon Certification (ISCC) is an independent, multi-stakeholder initiative and a leading certification system that ensures proper mass-balancing bookkeeping and reporting of recycled and renewable-based materials across the supply chain.
For more information about Kraton, please visit www.KRATON.com.
About Kraton CorporationKraton Corporation is a leading global producer of specialty polymers and high-value performance products derived from renewable resources. Kraton's polymers are used in a wide range of applications, including adhesives, coatings, consumer and personal care products, sealants, and lubricants, and medical, packaging, automotive, paving and roofing products. As the largest global provider in the pine chemicals industry, the company's pine-based specialty products are sold into adhesive, road and construction and tire markets, and it produces and sells a broad range of performance chemicals into markets that include fuel additives, oilfield chemicals, coatings, metalworking fluids and lubricants, inks, and mining. Kraton offers its products to a diverse customer base in over 70 countries worldwide.
*Kraton, the Kraton logo and design are all trademarks of Kraton Corporation, or its subsidiaries or affiliates, in one or more, but not all countries.
Media Contact: Mariam Stevens: (346) 435-8042
View original content to download multimedia:https://www.prnewswire.com/news-releases/kraton-receives-iscc-plus-certification-for-its-niort-manufacturing-facility-302412323.html
SOURCE Kraton Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Energenesis Biomedical to Unveil Promising Parkinson's Disease Therapy, ENERGI-F705PD, at BIO International 2025
TAIPEI, June 11, 2025 /PRNewswire/ -- Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company pioneering cellular energy restoration therapeutics, today announced its participation in the BIO International Convention 2025, taking place June 16–19 in Boston, MA. The company will be located at Booth #1645 within the Taiwan Pavilion, to showcase its innovative ENERGI Platform and provide a key update on its investigational Parkinson's disease (PD) therapy, ENERGI-F705PD, a first-in-class treatment with disease-modifying potential. Key Highlights: ENERGI-F705PD is a first-in-class, oral sustained-release therapy in development for Parkinson's disease, designed to address the underlying pathogenesis. Topline data from the Phase I trial in healthy subjects are anticipated in September 2025, following successful completion of recruitment. ENERGI-F705PD aims to combat the root causes of Parkinson's by reducing alpha-synuclein aggregation, enhancing antioxidant capacity, and boosting dopamine synthesis. "We are eager to present the exciting progress of our ENERGI-F705PD program at BIO International 2025," said Dr. Han-Min Chen, CEO of Energenesis Biomedical. "Parkinson's disease remains a challenging condition with significant unmet needs. Our approach focuses on restoring cellular energy and combating critical pathogenesis of PD, offering a potential disease-modifying solution for patients. We look forward to sharing our latest data and exploring potential partnerships that can accelerate the development of this important therapy." About ENERGI-F705PD ENERGI-F705PD is a novel small-molecule drug delivered in an oral sustained-release formulation. It is designed to enhance cellular ATP and antioxidant production by engaging the purine salvage, glycolysis, and pentose phosphate pathways. This multi-pronged mechanism of action directly addresses key pathological hallmarks of Parkinson's disease: Reduce and Prevent α-Synuclein Aggregation: Elevated ATP acts as a hydrotrope, helping prevent the intracellular aggregation of misfolded α-synuclein, a central pathogenic hallmark of PD. Increase Reducing Power (antioxidant): ENERGI-F705PD upregulates the pentose phosphate pathway (PPP), leading to increased NADPH production and enhanced cellular antioxidant defense. Increase Tyrosine Hydroxylase Expression/activity: By optimizing cellular energy metabolism and engaging the purine salvage pathway, ENERGI-F705PD also enhances the expression and activity of tyrosine hydroxylase (TH), the key enzyme in dopamine synthesis, thereby helping restore neurotransmitter levels in the brains of PD patients. About Energenesis Biomedical Energenesis Biomedical Co., Ltd. (TWSE: 6657) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that restore cellular energy and activate intrinsic repair mechanisms. By combining proprietary small-molecule innovation with AI-driven drug repurposing, Energenesis Biomedical aims to accelerate the development of treatments for unmet medical needs across various therapeutic areas, including neurodegenerative diseases, chronic wounds, and rare disorders. The company's robust pipeline includes: ENERGI-F705PD: Oral tablet for Parkinson's disease (Phase I) ENERGI-F703DFU: Gel for Diabetic foot ulcers (Phase III) ENERGI-F701: Tonic for Alopecia (Phase II completed) ENERGI-F703EB: Cream for Epidermolysis bullosa (EB), granted FDA Orphan Drug and Rare Pediatric Disease designation, and EMA orphan designation(Preparing for Phase II) For more information, please visit Contact: Business Development Team Email: partnership@ View original content: SOURCE ENERGENESIS BIOMEDICAL CO., LTD. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Marelli Initiates Voluntary U.S. Chapter 11 Proceedings to Strengthen Financial Position and Facilitate a Value-Maximizing Restructuring
Reaches Restructuring Support Agreement ("RSA") with Approximately 80% of Lenders Secures Commitment of $1.1 Billion in Debtor-in-Possession ("DIP") Financing from Lenders 100% of Secured Debt to be Eliminated Access to New Liquidity Designed to Support Normal Course Business Operations; Marelli will Continue Delivering Reliable, High-Performance Products for Customers TOKYO, June 11, 2025 /PRNewswire/ -- Marelli Holdings Co. Ltd. ("Marelli" or the "Company"), a global technology partner to the automotive industry, today announced that it has commenced voluntary chapter 11 cases in the United States Bankruptcy Court for the District of Delaware in order to comprehensively restructure its long‑term debt obligations. Approximately 80% of the Company's lenders have signed an agreement to support the restructuring (the "Restructuring Support Agreement"), which will deleverage Marelli's balance sheet and strengthen its liquidity position. Throughout this process and moving forward, Marelli does not expect any operational impact from the chapter 11 process, and the Company will continue to work closely with its customers, suppliers, and partners to innovate and invest in its portfolio of advanced technologies that will differentiate the vehicles of the future and transform mobility. A complete list of the Marelli affiliates involved in the chapter 11 cases can be found at "At Marelli, we have been proactive in making necessary adjustments to stabilize our financial position so that we can continue to deliver long-term benefits for our valued customers, partners and employees," said David Slump, President and CEO, Marelli. "While we are pleased with our recent progress and profitability, industry-wide market pressures have created a gap in working capital that must be addressed. After careful review of the Company's strategic alternatives, we have determined that entering the chapter 11 process is the best path to strengthen Marelli's balance sheet by converting debt to equity, while ensuring we continue operating as usual. Taking this action now provides access to new liquidity to fund our long-term growth and innovation pipeline, and ensures our customers and partners all over the world can continue to rely on Marelli for on-time delivery of advanced technologies that shape the vehicles of the future." Mr. Slump continued, "Marelli's focus on innovation, digitalization and technology has never been stronger. As we move through this process, we will continue to serve our customers and work with our suppliers and partners as they have come to expect. We are also grateful for the hard work and dedication of our employees who remain focused on delivering the best service possible." To support the Company during this process, Marelli has received a significant commitment for $1.1 billion in debtor-in-possession financing ("DIP Financing") from its lenders. This additional capital underscores lenders' continued support and confidence in the Company's underlying business and its long-term potential. Upon Court approval, the DIP Financing, coupled with cash generated from the Company's ongoing operations, is expected to provide sufficient liquidity to support the Company through the chapter 11 process. In addition to the DIP Financing, the Restructuring Support Agreement provides for a comprehensive deleveraging transaction through which the DIP Lenders will take ownership of the business upon emergence from chapter 11, subject to a 45-day overbid process. Marelli filed a number of customary first day motions seeking Court approval to continue its operations throughout the chapter 11 process, including, among other things, payment of employee wages and benefits without interruption and continuation of programs that are integral to customer relationships. The Company anticipates receiving Court approval for these requests and intends to continue honoring its obligations to key stakeholders post‑filing, including by satisfying payment obligations to suppliers for goods and services provided in accordance with customary terms after the filing. The Company will be working with its suppliers regarding obligations which arose before the chapter 11 filing to reach agreements on payment terms. Additional InformationAdditional information about Marelli's financial restructuring is available at Court filings and other information related to the proceedings, including the claims process, are available on a separate website administrated by the Company's claims agent, Verita, at by calling Verita's representatives toll-free at 877-606-7509 or +1 310-751-2626 for calls originating outside of the U.S. or Canada; or by emailing Verita at AdvisorsKirkland & Ellis LLP is serving as legal counsel to Marelli. PJT Partners Inc. is serving as financial advisor and Alvarez & Marsal LLC is serving as restructuring advisor to Marelli. Akin Gump Strauss Hauer & Feld LLP, Houlihan Lokey, and AlixPartners LLP are serving as advisors to an ad hoc group of lenders. About MarelliMarelli is a global mobility technology supplier to the automotive sector. With a strong and established track record in innovation and manufacturing excellence, our mission is to transform the future of mobility through working with customers and partners to create a safer, greener, and better-connected world. With around 45,000 employees worldwide, the Marelli footprint includes over 150 sites globally. View original content: SOURCE Marelli
Yahoo
4 hours ago
- Yahoo
Saab achieves AI milestone with Gripen E
STOCKHOLM, June 11, 2025 /PRNewswire/ -- Saab, in collaboration with Helsing, today announced the successful completion of the first three flights integrating Helsing's Artificial Intelligence (AI) agent `Centaur' into a Gripen E fighter jet. As part of Saab's `Project Beyond', the flights, where the first flight, was conducted on May 28, mark a significant advance in bringing AI capabilities to military aircraft. It is also yet another proof point of Gripen E's unparalleled ability to rapidly update software without disregarding safety requirements. During the flights, the Gripen E gave control to Centaur which successfully autonomously executed complex manoeuvres in a Beyond Visual Range (BVR) combat environment and cued the pilot to fire. "This is an important achievement for Saab, demonstrating our qualitative edge in sophisticated technologies by making AI deliver in the air. The swift integration and successful flight testing of Helsing's AI in a Gripen E exemplifies the accelerated capability gain you can get from our fighter. We are excited to continue developing and refining how this and other AI agents can be used, while once again showing how our fighters will outperform faster than the opponent can evolve," said Peter Nilsson, head of Advanced Programmes, from Saab's Aeronautics Business Area. Thanks to the unique design of Gripen E, the fighter can fly with the AI software onboard and fully integrated without being restricted to solely military test ranges or have to rely on an experimental X-plane to do flight trials with the software. "Within Project Beyond and other programmes, we utilise the power of software to rapidly explore and blur the lines between 'now' and the future; in software there are no generations, only speed," says Peter Nilsson. The third flight, conducted June 3, focused specifically on Centaur's performance, pitting it against a real Gripen D aircraft in a series of dynamic BVR scenarios with real-time data integration utilising sensor data to track the target aircraft. The team tested Centaur's adaptability by varying starting distances, speeds, aspects, and even disabling C2 data to assess its robustness. Saab's and Helsing's joint Project Beyond team was set up using Gripen E to explore how trustworthy AI can be used against future threats. The team will now analyse the flight data and continue training the AI agent to further enhance its BVR capabilities, with a further series of flights throughout the remainder of the year. The project, fully sponsored by Swedish Defence Material Administration (FMV), is part of the Swedish Concept programme for Future Fighter Systems. ContactSaab Press Centre+46 (0)734 180 018presscentre@ Saab is a leading defence and security company with an enduring mission, to help nations keep their people and society safe. Empowered by its 25,000 talented people, Saab constantly pushes the boundaries of technology to create a safer and more sustainable world. Saab designs, manufactures and maintains advanced systems in aeronautics, weapons, command and control, sensors and underwater systems. Saab is headquartered in Sweden. It has major operations all over the world and is part of the domestic defence capability of several nations. This information was brought to you by Cision The following files are available for download: CUE 25-032 Saab achieves AI milestone with Gripen E Gripen E flying with AI View original content: SOURCE Saab
